KEYNOTE-365 in mCRPC Results
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer ...
Author: obr
Added: 07/01/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts